Overslaan en naar de inhoud gaan

 Wetenschapelijke artikelen

Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancer.

Auteurs : Nuciforo P, Townend J, Piccart-Gebhart M, Fielding S, Gkolfi P, El-Abed S, de Azambuja E, Werutsky G, Bliss J, Moebus V, Colleoni M, Aspitia AM, Gomez H, Gombos A, Coccia-Portugal MA, Tseng LM, Kunz G, Lerzo G, Sohn J, Semiglazov V, Saura C, Kroep J, Ferro A, Cameron D, Gelber R, Huober J, Di Cosimo S
Jaar : 2023
Journal : Eur J Cancer
Volume : 181
Pagina's : 92-101

Impact of Anti-HER2 Therapy Alone and With Weekly Paclitaxel on the Ovarian Reserve of Young Women With HER2-Positive Breast Cancer.

Auteurs : Lambertini M, Ceppi M, Anderson RA, Cameron DA, Bruzzone M, Franzoi MA, Massarotti C, El-Abed S, Wang Y, Lecocq C, Nuciforo P, Rolyance R, Pusztai L, Sohn J, Latocca MM, Arecco L, Pistilli B, Ruddy KJ, Ballestrero A, Del Mastro L, Peccatori FA, Partridge AH, Saura C, Untch M, Piccart-Gebhart M, Di Cosimo S, de Azambuja E, Demeestere I
Jaar : 2023
Journal : J Natl Compr Canc Netw
Volume : 21
Pagina's : 33-41.e16

Medical oncology education in Europe: equipping medical oncologists to provide the best care for patients with cancer.

Auteurs : Jordan K, de Azambuja E, Amaral T, Strijbos M, Curigliano G, Lordick F
Jaar : 2023
Journal : Oncol Res Treat

Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab in early HER2-positive breast cancer in the APHINITY trial.

Auteurs : de Azambuja E, Agostinetto E, Procter M, Eiger D, Pondé N, Guillaume S, Parlier D, Lambertini M, Desmet A, Caballero C, Aguila C, Jerusalem G, Walshe JM, Frank E, Bines J, Loibl S, Piccart-Gebhart M, Ewer MS, Dent S, Plummer C, Suter T
Jaar : 2023
Journal : ESMO Open
Volume : 8
Pagina's : 100772

2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS).

Auteurs : Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, Boriani G, Cardinale D, Cordoba R, Cosyns B, Cutter DJ, de Azambuja E, de Boer RA, Dent SF, Farmakis D, Gevaert SA, Gorog DA, Herrmann J, Lenihan D, Moslehi J, Moura B, Salinger SS, Stephens R, Suter TM, Szmit S, Tamargo J, Thavendiranathan P, Tocchetti CG, van der Meer P, van der Pal HJH
Jaar : 2022
Journal : Eur Heart J
Volume : 43
Pagina's : 4229-4361

2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS).

Auteurs : Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, Boriani G, Cardinale D, Cordoba R, Cosyns B, Cutter DJ, de Azambuja E, de Boer RA, Dent SF, Farmakis D, Gevaert SA, Gorog DA, Herrmann J, Lenihan D, Moslehi J, Moura B, Salinger SS, Stephens R, Suter TM, Szmit S, Tamargo J, Thavendiranathan P, Tocchetti CG, van der Meer P, van der Pal HJH
Jaar : 2022
Journal : Eur Heart J Cardiovasc Imaging
Volume : 23
Pagina's : e333-e465

HER2-Low Breast Cancer: Where Are We?

Auteurs : Molinelli C, Jacobs F, Marchiò C, Pitto F, Cosso M, Spinaci S, de Azambuja E, Schettini F, Agostinetto E, Lambertini M
Jaar : 2022
Journal : Breast Care (Basel)
Volume : 17
Pagina's : 533-545

Changes in anticancer treatment plans in patients with solid cancer hospitalized with COVID-19: analysis of the nationwide BSMO-COVID registry providing lessons for the future.

Auteurs : Geukens T, Brandão M, Laenen A, Collignon J, Van Marcke C, Louviaux I, Demey W, Van Wambeke S, Schrijvers D, Lecomte S, Mebis J, Rutten A, Fontaine C, Lybaert W, Aspeslagh S, Goeminne JC, Van den Bulck H, Seront E, De Backer L, De Roock W, Ignatiadis M, Prenen H, Van Beckhoven D, Heijlen M, Verheezen J, Rottey S, Punie K, de Azambuja E
Jaar : 2022
Journal : ESMO Open
Volume : 7
Pagina's : 100610

Post-Neoadjuvant Treatment Strategies for Patients with Early Breast Cancer.

Auteurs : Agostinetto E, Jacobs F, Debien V, De Caluwé A, Pop CF, Catteau X, Aftimos P, de Azambuja E, Buisseret L
Jaar : 2022
Journal : Cancers (Basel)
Volume : 14

Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer.

Auteurs : Agostinetto E, Losurdo A, Nader-Marta G, Santoro A, Punie K, Barroso R, Popovic L, Solinas C, Kok M, de Azambuja E, Lambertini M
Jaar : 2022
Journal : Expert Opin Investig Drugs
Volume : 31
Pagina's : 567-591

Implication of body mass index (BMI) on the biological and clinical effects of endocrine therapy plus abemaciclib as neoadjuvant therapy for early breast cancer patients.

Auteurs : Franzoi MA, Lambertini M, Ceppi M, Bruzzone M, de Azambuja E
Jaar : 2022
Journal : Breast Cancer Res Treat
Volume : 192
Pagina's : 457-462

Authors' Reply To the Letters to the Editor by Puklin et al and by Iyengar and Ligibel.

Auteurs : Martel S, Lambertini M, de Azambuja E
Jaar : 2022
Journal : J Natl Compr Canc Netw
Volume : 20
Pagina's : xlv-xlvi

How we treat patients with metastatic HER2-positive breast cancer.

Auteurs : Nader-Marta G, Martins-Branco D, de Azambuja E
Jaar : 2022
Journal : ESMO Open
Volume : 7
Pagina's : 100343

Evaluation of Cardiotoxicity in HER-2-Positive Breast Cancer Patients Treated With Radiation Therapy and Trastuzumab.

Auteurs : Bachir B, Anouti S, Abi Jaoude J, Kayali M, Tfayli A, de Azambuja E, Poortmans P, Zeidan YH
Jaar : 2022
Journal : Int J Radiat Oncol Biol Phys
Volume : 113
Pagina's : 135-142

Beta-2 Adrenergic Receptor Gene Expression in HER2-Positive Early-Stage Breast Cancer Patients: A Post-hoc Analysis of the NCCTG-N9831 (Alliance) Trial.

Auteurs : Caparica R, Ma Y, de Angelis C, Richard F, Desmedt C, Awada A, Piccart M, Perez EA, Moreno-Aspitia A, Badve S, Thompson EA, de Azambuja E
Jaar : 2022
Journal : Clin Breast Cancer
Volume : 22
Pagina's : 308-318

Predictive Role of CD36 Expression in HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Trastuzumab.

Auteurs : Ligorio F, Di Cosimo S, Verderio P, Ciniselli CM, Pizzamiglio S, Castagnoli L, Dugo M, Galbardi B, Salgado R, Loi S, Michiels S, Triulzi T, Tagliabue E, El-Abed S, Izquierdo M, de Azambuja E, Nuciforo P, Huober J, Moscetti L, Janni W, Coccia-Portugal MA, Corsetto PA, Belfiore A, Lorenzini D, Daidone MG, Vingiani A, Gianni L, Pupa SM, Bianchini G, Pruneri G, Vernieri C
Jaar : 2022
Journal : J Natl Cancer Inst
Volume : 114
Pagina's : 1720-1727

Ovarian Function Suppression: A Deeper Consideration of the Role in Early Breast Cancer and its Potential Impact on Patient Outcomes: A Consensus Statement from an International Expert Panel.

Auteurs : Arboleda B, Bartsch R, de Azambuja E, Hamilton E, Harbeck N, Klemp J, Knauer M, Kuemmel S, Mahtani R, Schwartzberg L, Villarreal-Garza C, Wolff A
Jaar : 2022
Journal : Oncologist
Volume : 27
Pagina's : 722-731

PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer.

Auteurs : Agostinetto E, Ameye L, Martel S, Aftimos P, Pondé N, Maurer C, El-Abed S, Wang Y, Vicente M, Chumsri S, Bliss J, Kroep J, Colleoni M, Petrelli F, Del Mastro L, Moreno-Aspitia A, Piccart M, Paesmans M, de Azambuja E, Lambertini M
Jaar : 2022
Journal : NPJ Breast Cancer
Volume : 8
Pagina's : 87

Immune response to anti-SARS-CoV-2 prime-vaccination in patients with cancer: a systematic review and meta-analysis.

Auteurs : Martins-Branco D, Nader-Marta G, Tecic Vuger A, Debien V, Ameye L, Brandão M, Punie K, Loizidou A, Willard-Gallo K, Spilleboudt C, Awada A, Piccart M, de Azambuja E
Jaar : 2022
Journal : J Cancer Res Clin Oncol
Pagina's : 1-6

Efficacy of tyrosine kinase inhibitors for the treatment of patients with HER2-positive breast cancer with brain metastases: a systematic review and meta-analysis.

Auteurs : Nader-Marta G, Martins-Branco D, Agostinetto E, Bruzzone M, Ceppi M, Danielli L, Lambertini M, Kotecki N, Awada A, de Azambuja E
Jaar : 2022
Journal : ESMO Open
Volume : 7
Pagina's : 100501